Skip to main content

Table 4 Indirect comparison in ORR

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

A0.21 (0.051, 0.85)2.06 (1.20, 2.81)0.72 (0.35, 1.5)0.87 (0.28, 2.8)1.4 (0.67, 2.8)2.5 (1.3, 4.9)1.1 (0.37, 3.3)1.1 (0.37, 3.5)2.0 (0.62, 6.2)2.5 (0.77, 8.2)
4.7 (1.2, 20.0)B7.1 (1.9, 28.0)3.4 (1.0, 12.0)4.1 (0.71, 24.0)6.5 (1.4, 31.0)12.0 (2.8, 52.0)5.2 (0.96, 29.0)5.4 (1.3, 24.0)9.3 (1.7, 53.0)12.0 (2.1, 69.0)
0.49 (0.36, 0.83)0.14 (0.036, 0.53)C0.48 (0.26, 0.88)0.58 (0.19, 1.7)0.92 (0.45, 1.9)1.7 (0.95, 2.9)0.73 (0.26, 2.0)0.76 (0.26, 2.2)1.3 (0.44, 3.9)1.7 (0.54, 5.1)
1.4 (0.68, 2.8)0.30 (0.085, 0.96)2.1 (1.1, 3.9)D1.2 (0.34, 4.2)1.9 (0.74, 4.9)3.5 (1.5, 8.0)1.5 (0.46, 5.1)1.6 (0.67, 3.8)2.7 (0.78, 9.7)3.5 (0.96, 12.0)
1.2 (0.36, 3.6)0.24 (0.042, 1.4)1.7 (0.58, 5.2)0.82 (0.24, 2.9)E1.6 (0.42, 5.9)2.9 (0.83, 9.9)1.3 (0.28, 5.6)1.3 (0.28, 6.1)2.3 (0.48, 11.0)2.8 (0.60, 14.0)
0.72 (0.35, 1.5)0.15 (0.032, 0.70)1.1 (0.53, 2.2)0.52 (0.20, 1.3)0.63 (0.17, 2.4)F1.8 (0.73, 4.6)0.80 (0.23, 2.8)0.82 (0.23, 3.0)1.4 (0.39, 5.2)1.8 (0.48, 6.8)
0.40 (0.20, 0.78)0.085 (0.019, 0.36)0.60 (0.34, 1.1)0.29 (0.12, 0.66)0.35 (0.10, 1.2)0.56 (0.22, 1.4)G0.44 (0.14, 1.4)0.46 (0.14, 1.5)0.79 (0.23, 2.7)0.99 (0.28, 3.5)
0.91 (0.30, 2.7)0.19 (0.034, 1.0)1.4 (0.49, 3.8)0.65 (0.20, 2.2)0.79 (0.18, 3.5)1.3 (0.36, 4.4)2.3 (0.70, 7.4)H1.0 (0.24, 4.5)1.8 (0.40, 8.1)2.2 (0.49, 10.0)
0.88 (0.29, 2.7)0.19 (0.042, 0.80)1.3 (0.46, 3.8)0.63 (0.27, 1.5)0.77 (0.16, 3.5)1.2 (0.34, 4.3)2.2 (0.66, 7.3)0.97 (0.22, 4.2)I1.7 (0.37, 8.0)2.2 (0.47, 10.0)
0.51 (0.16, 1.6)0.11 (0.019, 0.61)0.76 (0.25, 2.3)0.37 (0.10, 1.3)0.44 (0.094, 2.1)0.70 (0.19, 2.6)1.3 (0.37, 4.4)0.56 (0.12, 2.5)0.58 (0.12, 2.7)J1.3 (0.26, 6.1)
0.40 (0.12, 1.3)0.085 (0.014, 0.48)0.60 (0.20, 1.8)0.29 (0.080, 1.0)0.35 (0.073, 1.7)0.56 (0.15, 2.1)1.0 (0.28, 3.5)0.45 (0.097, 2.0)0.46 (0.097, 2.1)0.79 (0.16, 3.9)K
  1. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, G = Bev + Tax+Cap, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+ Eve, K = Bev + Tax+Tre
  2. The values represent OR (95%CI), and the values in bold represent OR (95%CI) has significant statistical difference in indirect comparison
  3. Bev bevacizumab, Cap capecitabine, Tax taxanes, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Eve everolimus, Tre trebananib, Mot motesanib
\